GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM Vaccine Co Ltd (HKSE:06660) » Definitions » Stock Based Compensation

AIM Vaccine Co (HKSE:06660) Stock Based Compensation : HK$0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is AIM Vaccine Co Stock Based Compensation?

AIM Vaccine Co's Stock Based Compensation for the six months ended in Dec. 2024 was HK$0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 was HK$0 Mil.


AIM Vaccine Co Stock Based Compensation Historical Data

The historical data trend for AIM Vaccine Co's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM Vaccine Co Stock Based Compensation Chart

AIM Vaccine Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Stock Based Compensation
Get a 7-Day Free Trial 27.83 1,165.85 252.11 -15.53 -

AIM Vaccine Co Semi-Annual Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only 183.31 -23.91 8.37 - -

AIM Vaccine Co Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0 Mil.


AIM Vaccine Co Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of AIM Vaccine Co's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


AIM Vaccine Co Business Description

Traded in Other Exchanges
N/A
Address
2 Ronghua South Road, 26th Floor, Building T6, Han’s Plaza, Economic Technological Development Area, Beijing, CHN
AIM Vaccine Co Ltd is a top full-chain vaccine corporation in China with businesses covering the whole industrial chain, ranging from research and development to manufacturing and commercialization. The Vaccine products include Recombinant HBV Vaccines, Freeze-dried Human Rabies Vaccine, Inactivated HAV Vaccines, Group A, C, Y, and W135 MPSV, Bivalent Inactivated HFRS Vaccine, and Mumps Vaccine. It generates the majority of its revenues in the PRC.
Executives
Shang Hai Xun Jing Qi Ye Guan Li Zhong Xin You Xian He Huo 2201 Interest of corporation controlled by you
Xi Zang Ying Feng Shi Ye You Xian Gong Si 2101 Beneficial owner
Yang Aihua 2201 Interest of corporation controlled by you
Zhao Yin Jin Rong Kong Gu Shen Zhen You Xian Gong Si 2201 Interest of corporation controlled by you
Zhao Shang Yin Xing Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong You Xian Gong Si 2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si 2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Zi Ben Guan Li Shen Zhen You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Shi Bei Lun Qu Guo You Zi Ben Yun Ying You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Bao Shui Qu Kong Gu You Xian Gong Si 2101 Beneficial owner
Chang Wei 2201 Interest of corporation controlled by you
Wang Aijun 2201 Interest of corporation controlled by you
China Merchants Bank Co., Ltd. 2201 Interest of corporation controlled by you
Zhang Kuo 2201 Interest of corporation controlled by you
Zhang Chong 2201 Interest of corporation controlled by you

AIM Vaccine Co Headlines

No Headlines